Source:http://linkedlifedata.com/resource/pubmed/id/17301952
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-3-5
|
pubmed:abstractText |
JNK1 and JNK2 have distinct effects on activation, differentiation and function of CD8+ T cells. Our early studies demonstrated that JNK1 is required for CD8+ T cell-mediated tumor immune surveillance. However, the role of JNK2 in CD8+ T cell response and effector functions, especially in anti-tumor immune response, is unknown. To define the role of JNK2 in antigen-specific immune response, we have investigated CD8+ T cells from OT-1 CD8+ transgenic mice in response to either high- or low-affinity peptides. JNK2-/- CD8+ T cells proliferated better in response to both peptides, with more cell division and less cell death. In addition, JNK2-/- CD8+ T cells produced higher levels of IFN-gamma, which is associated with increased expression of T-bet and Eomesodermin (Eomes). Moreover, JNK2-/- CD8+ T cells expresses high levels of granzyme B and show increased CTL activity. Finally, the enhanced expansion and effector function of JNK2-/- CD8+ T cells was further evidenced by their capacity to delay tumor growth in vivo. In summary, our results demonstrate that JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0014-2980
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
818-29
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17301952-Animals,
pubmed-meshheading:17301952-CD8-Positive T-Lymphocytes,
pubmed-meshheading:17301952-Cell Line, Tumor,
pubmed-meshheading:17301952-Cell Survival,
pubmed-meshheading:17301952-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:17301952-Down-Regulation,
pubmed-meshheading:17301952-Growth Inhibitors,
pubmed-meshheading:17301952-Melanoma, Experimental,
pubmed-meshheading:17301952-Mice,
pubmed-meshheading:17301952-Mice, Inbred C57BL,
pubmed-meshheading:17301952-Mice, Knockout,
pubmed-meshheading:17301952-Mice, Transgenic,
pubmed-meshheading:17301952-Mitogen-Activated Protein Kinase 9
|
pubmed:year |
2007
|
pubmed:articleTitle |
JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response.
|
pubmed:affiliation |
Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT 06520-8031, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|